CA2223510C - Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease - Google Patents

Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease Download PDF

Info

Publication number
CA2223510C
CA2223510C CA002223510A CA2223510A CA2223510C CA 2223510 C CA2223510 C CA 2223510C CA 002223510 A CA002223510 A CA 002223510A CA 2223510 A CA2223510 A CA 2223510A CA 2223510 C CA2223510 C CA 2223510C
Authority
CA
Canada
Prior art keywords
salen
activity
antioxidant
catalase
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002223510A
Other languages
English (en)
French (fr)
Other versions
CA2223510A1 (en
Inventor
Bernard Malfroy-Camine
Susan Robert Doctrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eukarion Inc
Original Assignee
Eukarion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eukarion Inc filed Critical Eukarion Inc
Publication of CA2223510A1 publication Critical patent/CA2223510A1/en
Application granted granted Critical
Publication of CA2223510C publication Critical patent/CA2223510C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CA002223510A 1995-06-07 1996-06-06 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease Expired - Fee Related CA2223510C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/485,489 US5696109A (en) 1992-12-07 1995-06-07 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US08/485,489 1995-06-07
PCT/US1996/010267 WO1996040149A1 (en) 1995-06-07 1996-06-06 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease

Publications (2)

Publication Number Publication Date
CA2223510A1 CA2223510A1 (en) 1996-12-19
CA2223510C true CA2223510C (en) 2008-05-20

Family

ID=23928377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223510A Expired - Fee Related CA2223510C (en) 1995-06-07 1996-06-06 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease

Country Status (6)

Country Link
US (6) US5696109A (OSRAM)
EP (1) EP0831836A4 (OSRAM)
JP (1) JP4160115B2 (OSRAM)
AU (2) AU719450B2 (OSRAM)
CA (1) CA2223510C (OSRAM)
WO (2) WO1996040148A1 (OSRAM)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582786B2 (en) * 1992-12-07 2009-09-01 Eukarion Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6013623A (en) * 1997-02-27 2000-01-11 The Trustees Of Columbia University In The City Of New York Use of heme-peptides to prevent or retard disease associated with oxidative stress
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
IL135949A0 (en) 1997-11-03 2001-05-20 Univ Duke Substituted porphyrins
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
TW408203B (en) * 1998-04-06 2000-10-11 Ciba Sc Holding Ag Process for treating textile materials and the relevant compounds
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
US6479477B1 (en) 1998-04-24 2002-11-12 Duke University Substituted porphyrins
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
GB9817845D0 (en) * 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
IL144503A0 (en) 1999-01-25 2002-05-23 Nat Jewish Med & Res Center Substituted porphyrins
WO2000053574A1 (en) * 1999-03-08 2000-09-14 Ciba Specialty Chemicals Holding Inc. Manganese complexes of salen ligands and the use thereof
US20040110722A1 (en) * 1999-05-27 2004-06-10 Ornberg Richard L. Modified hyaluronic acid polymers
JP2003500174A (ja) * 1999-05-27 2003-01-07 フアルマシア・コーポレーシヨン スーパーオキシド・ジスムターゼ模倣体で修飾された生体材料
AUPQ180499A0 (en) 1999-07-23 1999-08-19 Biomolecular Research Institute Limited Beta-amyloid peptide inhibitors
US6179804B1 (en) * 1999-08-18 2001-01-30 Oxypatch, Llc Treatment apparatus for wounds
WO2002006301A2 (en) * 2000-06-30 2002-01-24 University Of Cincinnati Peptides with antioxidant and antimicrobial properties
KR100386552B1 (ko) * 2000-08-03 2003-06-02 한국화인케미칼주식회사 올레핀의 비대칭 에폭시화 반응에 유용한 고분자 키랄살렌 유도체
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
WO2002053142A2 (en) * 2001-01-05 2002-07-11 Metaphore Pharmaceuticals, Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
DK1392328T3 (da) * 2001-01-19 2009-11-09 Nat Jewish Health Medikament til beskyttelse i radioterapi
WO2002058686A2 (en) * 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20020150582A1 (en) * 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
EP1439842A4 (en) 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
AU2002315001A1 (en) * 2001-06-08 2002-12-23 Metaphore Pharmaceuticals, Inc. Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
AU784852B2 (en) * 2001-08-10 2006-07-06 Mars, Incorporated Canine support diet
US20040132706A1 (en) * 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
US20050222060A1 (en) * 2002-03-15 2005-10-06 Bot Adrian L Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP1513537A4 (en) * 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
AU2003247144B2 (en) * 2002-08-02 2007-11-29 Mor Research Applications Ltd. Treatment of multiple sclerosis with brain targeted anti oxidant compounds
WO2004017959A2 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
US6964365B2 (en) * 2003-05-07 2005-11-15 Mt Pleasant Gregory Library card holder
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
ITTO20040124A1 (it) * 2004-03-01 2004-06-01 Medestea Internaz Srl Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative
FR2875500A1 (fr) * 2004-09-21 2006-03-24 Centre Nat Rech Scient Complexe chiraux macrocycliques utilisables comme catalyseurs
US20060121016A1 (en) * 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
US9044462B2 (en) 2004-12-08 2015-06-02 Avent, Inc. Method for oxygen treatment of intact skin
US20060121101A1 (en) * 2004-12-08 2006-06-08 Ladizinsky Daniel A Method for oxygen treatment of intact skin
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
WO2007057902A2 (en) * 2005-11-18 2007-05-24 Apexum Ltd. Ablating apparatus particularly useful for removal of dental periapical lesions
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
GB0607096D0 (en) * 2006-04-07 2006-05-17 Imp Innovations Ltd Compound
US8246975B2 (en) 2006-06-28 2012-08-21 Ihi Corporation Drug, drug guidance system, magnetic detection system, and drug design method
US7724491B2 (en) * 2006-09-14 2010-05-25 Earth Fx, Inc. Method of treating inflammation and autoimmune diseases
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US8252780B2 (en) * 2006-12-01 2012-08-28 Women & Infants' Hospital Organometallic complexes as therapeutic agents
EP1949899A1 (en) * 2007-01-23 2008-07-30 Freie Universität Berlin Metal salophen complexes use in prevention and treatment of cancer
JP4753922B2 (ja) * 2007-09-27 2011-08-24 肇 小座野 化粧料用原料
US20090169484A1 (en) * 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP2009274962A (ja) * 2008-05-12 2009-11-26 Yoshihiro Ishikawa 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
KR101646066B1 (ko) 2008-05-23 2016-08-05 내셔날 쥬이쉬 헬스 알킬화 종으로의 노출과 관련된 상해를 치료하는 방법
US20100098768A1 (en) * 2008-10-16 2010-04-22 Clarkson University Method of neuroprotection from oxidant injury using metal oxide nanoparticles
JP5513405B2 (ja) * 2008-11-20 2014-06-04 株式会社Ｉｈｉ 自己磁性金属サレン錯体化合物
KR101050273B1 (ko) 2008-11-21 2011-07-19 세종대학교산학협력단 살렌 전이금속 착화합물, 및 그 제조 방법
US9132090B2 (en) * 2009-01-13 2015-09-15 Chetan Majmudar Propofol based anesthetic with preservative
KR20120046795A (ko) * 2009-09-04 2012-05-10 무니색하 매다사니 신경퇴행성 또는 신경근 퇴행성 질환의 치료 방법 및 이러한 질환들을 치료하기 위한 치료제
JP5680065B2 (ja) * 2010-04-28 2015-03-04 株式会社Ihi 抗脳腫瘍薬剤
JP5873656B2 (ja) * 2011-06-13 2016-03-01 株式会社Ihi 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
KR102024510B1 (ko) 2011-07-18 2019-11-14 사우디 아람코 테크놀로지스 컴퍼니 금속 착체
WO2013016544A2 (en) 2011-07-27 2013-01-31 University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
JP6046338B2 (ja) 2011-10-27 2016-12-14 株式会社Ihi ラジカル抑制剤
CA2849773C (en) 2011-10-28 2020-10-20 E. I. Du Pont De Nemours And Company Treated inorganic core particles having improved dispersability
JP5881840B2 (ja) * 2011-10-28 2016-03-09 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ 分散性の改善された処理済み無機顔料およびその紙製品における使用
CA2849758C (en) 2011-10-28 2020-10-20 Michael Patrick Diebold Treated inorganic pigments having improved dispersability and use thereof in coating compositions
KR102096761B1 (ko) 2012-08-24 2020-04-03 사우디 아람코 테크놀로지스 컴퍼니 금속 착물
CZ304883B6 (cs) * 2013-06-10 2014-12-29 Univerzita PalackĂ©ho Salophenové komplexy železa s heterocyklickými N-donorovými ligandy, způsob jejich přípravy a jejich použití jako léčiv v protinádorové terapii
EP3089666B1 (en) 2013-12-31 2020-08-19 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
JP5806356B2 (ja) * 2014-03-10 2015-11-10 株式会社Ihi 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
CA2988599A1 (en) * 2015-06-05 2016-12-08 Glenn A. Goldstein Use of n-acetylcysteine amide in the treatment of acetaminophen overdose
US11154619B2 (en) 2017-02-17 2021-10-26 Creighton University Liposomal compositions with light illumination-induced drug release
CN113061259B (zh) * 2021-03-14 2022-03-29 华中科技大学同济医学院附属协和医院 用于缺血性脑卒中治疗的金属有机框架材料的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106841A (en) * 1986-05-13 1992-04-21 Chai-Tech Corporation Antiviral compositions and method for their use
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
ES2171159T3 (es) * 1991-08-26 2002-09-01 Res Corp Technologies Inc Procedimiento para la preparacion de epoxicromanos con un catalizador quiral.
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease

Also Published As

Publication number Publication date
WO1996040149A1 (en) 1996-12-19
US20020002157A1 (en) 2002-01-03
US20050249796A1 (en) 2005-11-10
AU719450B2 (en) 2000-05-11
US5696109A (en) 1997-12-09
US6573257B2 (en) 2003-06-03
US20030216371A1 (en) 2003-11-20
EP0831836A4 (en) 2000-09-27
WO1996040148A1 (en) 1996-12-19
JPH11507646A (ja) 1999-07-06
AU6332896A (en) 1996-12-30
AU6272596A (en) 1996-12-30
US20090311230A1 (en) 2009-12-17
JP4160115B2 (ja) 2008-10-01
CA2223510A1 (en) 1996-12-19
EP0831836A1 (en) 1998-04-01
US6046188A (en) 2000-04-04
US6900198B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
CA2223510C (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5827880A (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6589948B1 (en) Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US5834509A (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
WO1994013300A9 (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
AU2002239381A1 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
US7582786B2 (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140606